MorphoSys' Management Board And Supervisory Board Recommend Shareholders Accept Public Takeover Offer By Novartis For €68.00 Per Share In Cash
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion
Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively
Acceptance period has commenced and will end on May 13, 2024, at 24:00 hours CEST
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 11, 2024 / The Management Board and Supervisory Board of MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total equity value of € 2.7 billion (the "Takeover Offer"). The offer price corresponds to a premium of 94% and 142% on the volume-weighted average price during the last month and three months, respectively, as of the unaffected January 25, 2024, closing price.
"The proposed acquisition by Novartis is in the best interest of MorphoSys, our shareholders and cancer patients - helping to accelerate commercial and development opportunities across our promising oncology pipeline," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. "The offer made by Novartis provides MorphoSys shareholders with an opportunity to realize significant value upfront and with certainty. After conducting a thorough assessment of the offer document, we unanimously conclude that the offer, including the offer price, is highly attractive and equitable. We recommend our shareholders accept this offer."